Tools   Select Another Resource Report Type

https://sbpdiscovery.org/tag/neuroscienceandagingresearchcenter/

Center that translates basic science discoveries into new treatments to extend lifespan and to combat degenerative disorders associated with aging or development. Their researchers are discovering the etiological pathways as well as small-molecule and stem cell-based treatments to address the clinical unmet need of these patients. The Center uses a team based approach to apply their expertise in stem cells to develop therapies for new treatments for stroke and Parkinson's disease. They are also performing high-throughput screens to identify new molecules to protect the synapses of nervesthe connections between nerves that mediate movement, memory and cognition for Alzheimer's, Parkinson's and autism. By studying the links between Down syndrome and Alzheimer's disease, they are exploring new treatments to improve cognition in both disorders. Their collaborations with clinical partners enable them to test new discoveries in human trials, with a goal to improve the lives of patients and families affected by neurodegenerative disease and aging disorders.

Proper citation: Sanford-Burnham Neuroscience and Aging Research Center (RRID:SCR_001688) Copy   

•   Source: SciCrunch Registry

https://radiology.duke.edu/research/centers-and-shared-resources/center-advanced-magnetic-resonance-development

Research facility of the Department of Radiology at the Duke University Medical Center (DUMC) providing access to a whole-body, commercially manufactured 3 Tesla (Trio, Siemens Medical Systems) MR Imaging and Spectroscopy System with full research capability. The Center is fully equipped to perform clinical and research MR imaging or spectroscopy studies on humans or large animals. A full range of monitoring, anesthesia, RF coil development, computer and instrumental control facilities as well as MR research technologists and physics/chemistry consultation are available to Department of Radiology researchers and their collaborators.

Proper citation: CAMRD (RRID:SCR_001713) Copy   

•   Source: SciCrunch Registry

http://www.nature.com/jcbfm/index.html

The Journal of Cerebral Blood Flow & Metabolism stands at the interface between basic and clinical neurovascular research, and features timely and relevant research highlighting experimental, theoretical, and clinical aspects of brain circulation, metabolism and imaging. The journal is relevant to any physician or scientist with an interest in brain function, cerebrovascular disease, cerebral vascular regulation and brain metabolism, including neurologists, neurochemists, physiologists, pharmacologists, anesthesiologists, neuroradiologists, neurosurgeons, neuropathologists and neuroscientists. On this website, you will find the full text of articles published online weekly, in advance of print, the current issue and an archive of previous issues. You can also find general information about the journal, and more detailed information for readers, authors, referees, librarians, advertisers, and journalists. Most articles are published online before they appear in print. New papers are uploaded weekly to the Advance online publication (AOP) page. The online publication date is specified for each paper; these versions are identical to the printed version in every respect and may be cited using the digital object identifier (DOI).

Proper citation: Journal of Cerebral Blood Flow and Metabolism (RRID:SCR_001769) Copy   

•   Source: SciCrunch Registry

http://qnl.bu.edu/obart

Tool that provides an interactive method to examine quantitative relationships between brain regions defined by different digital atlases or parcellation methods. Its current focus is for human brain imaging, though the techniques generalize to other domains. The method offers a quantitative answer to the nomenclature problem in neuroscience by comparing brain parts on the basis of their geometrical definitions rather than on the basis of name alone. Thus far these tools have been used to quantitatively compare eight distinct parcellations of the International Consortium for Brain Mapping (ICBM) single-subject template brain, each created using existing atlasing methods. This resources provides measures of global and regional similarity, and offers visualization techniques that allow users to quickly identify the correspondences (or lack of correspondences) between regions defined by different atlases.

Proper citation: OBART (RRID:SCR_001903) Copy   

•   Source: SciCrunch Registry

https://www.mdcalc.com/calc/715/nih-stroke-scale-score-nihss

The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurological deficit. The NIHSS was originally designed as a research tool to measure baseline data on patients in acute stroke clinical trials. Now, the scale is also widely used as a clinical assessment tool to evaluate acuity of stroke patients, determine appropriate treatment, and predict patient outcome. The NIHSS can be used as a clinical stroke assessment tool to evaluate and document neurological status in acute stroke patients. The stroke scale is valid for predicting lesion size and can serve as a measure of stroke severity. The NIHSS has been shown to be a predictor of both short and long term outcome of stroke patients. Additionally, the stroke scale serves as a data collection tool for planning patient care and provides a common language for information exchanges among healthcare providers. Performing the scale takes between 5-8 minutes. Emergency physicians and nurses, neurologists, neuroscience nurses and other stroke team members are typical examples of who should be certified to perform the NIHSS. The NINDS/NIH training and testing DVD can be obtained from the National Institute of Neurological Disorders and Stroke. Sponsors: NIHSS is supported by the National Institute of Neurological Disorders and Stroke (NINDS).

Proper citation: National Institutes of Health Stroke Scale (RRID:SCR_001804) Copy   

•   Source: SciCrunch Registry

http://www.aspergillus-genomes.org.uk/

A resource for viewing annotated genes arising from various Aspergillus sequencing and annotation projects, resulting from the merging of Central Aspergillus Data REpository (CADRE) and The Aspergillus Website, which took place in June 2008. The principal role of CADRE is to aid the Aspergillus research community by managing Aspergillus genome data and by providing visualization tools, ranging from relatively simple annotation displays to more complex data integration displays. In contrast, The Aspergillus Website provides a range of information to the medical community (i.e., clinicians, patients and scientists) regarding the genus Aspergillus and the diseases, such as Aspergillosis, that it can cause. CADRE has been implemented using the Ensembl v22 suite. This suite comprises: * a database schema, which has been devised for storing annotated eukaryotic genomes. The schema is implemented with the MySQL relational database management system. * several specialized programming modules for building interfaces (i.e., BioPerl and Ensembl API modules). * a series of programs (i.e., Perl CGI scripts using the API modules) for viewing genomic data within a web browser., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Aspergillus Genomes (RRID:SCR_001880) Copy   

•   Source: SciCrunch Registry

http://www.va.gov/visn4mirecc/

The mission of the VISN 4 MIRECC is the treatment and prevention of comorbid medical, mental health, and/or substance use disorders, with the aim of improving the health, quality of life, and outcomes of healthcare services for veterans with mental illness. This is accomplished through the integration of basic, clinical, and services research and educational and clinical programs. The objectives of this MIRECC are: * Develop new empirical knowledge that can be directly applied to improve the clinical care of veterans * Provide education to providers and trainees to enhance the delivery of high quality healthcare to veterans * Impact public health in terms of veterans' mental health and quality of life * Serve as a national resource in education, research, and treatment of patients with comorbidity, and as a replicable model of excellence in clinical and educational programs Examine causal factors in the development of comorbid conditions. Assess impact of comorbidity on: * the identification and classification of disorders * the development and implementation of treatments * access to treatment and the impact of treatments on outcomes Sponsors: This work is supported by the US Department of Veterans Affairs

Proper citation: VISN 4 MIRECC (RRID:SCR_001970) Copy   

•   Source: SciCrunch Registry

http://library.med.utah.edu/WebPath/webpath.html#MENU

This popular web resource includes over 1900 images along with text, tutorials, laboratory exercises, and examination items for self-assessment that demonstrate gross and microscopic pathologic findings associated with human disease conditions. Content includes pathology cases (surgical pathology, autopsy, cytopathology, forensic pathology, clinical pathology) at the University of Utah Health Sciences Center and affiliated hospitals and laboratories, and from contributors at other institutions worldwide. The content at this web site will assist a medical student in achievement of an important goal: passing step 1 of the USMLE examination required to become licensed as a physician. This site was conceived from the necessity to create useful multimedia teaching resources for medical students at the University of Utah for use in the pathology courses given in the second year of the curriculum.

Proper citation: WebPath - The Internet Pathology Laboratory for Medical Education (RRID:SCR_002033) Copy   

•   Source: SciCrunch Registry

http://sourceforge.net/projects/dmetanalyzer/

Software tool for the automatic association analysis among the variation of the patient genomes and the clinical conditions of patients, i.e. the different response to drugs. The system allows: (i) to automatize the workflow of analysis of DMET (drug metabolism enzymes and transporters)-SNP (Single Nucleotide Polymorphism) data avoiding the use of multiple tools; (ii) the automatic annotation of DMET-SNP data and the search in existing databases of SNPs (e.g. dbSNP), (iii) the association of SNP with pathway through the search in PharmaKGB, a major knowledge base for pharmacogenomic studies. It has a simple graphical user interface that allows users (doctors/biologists) to upload and analyze DMET files produced by Affymetrix DMET-Console in an interactive way.

Proper citation: DMET-Analyzer (RRID:SCR_002030) Copy   

•   Source: SciCrunch Registry

https://datashare.nida.nih.gov

Website which allows data from completed clinical trials to be distributed to investigators and public. Researchers can download de-identified data from completed NIDA clinical trial studies to conduct analyses that improve quality of drug abuse treatment. Incorporates data from Division of Therapeutics and Medical Consequences and Center for Clinical Trials Network.

Proper citation: NIDA Data Share (RRID:SCR_002002) Copy   

•   Source: SciCrunch Registry

https://meded.ucsd.edu/index.cfm/asa/dcp/goddp/

The UCSD School of Medicine are dedicated to producing future leaders in all areas of medicine. As such, the School promotes the pursuit of dual degrees, either in the Medical School's own graduate degree programs or programs offered in other disciplines in the institution. In addition to the study of medicine, the School of Medicine actively encourages its student body to explore broadly in various scholarly areas related to the biomedical sciences. The goal of this additional training is to produce graduates who will bring fresh, innovative ideas to the research laboratory, the public health sector, the humanities and the social sciences, and the business environment. Students may elect to obtain advanced degrees in the following areas: * Biomedical Sciences * Masters in Bioengineering * Masters in Public Health * Masters in Leadership of Health Care Organizations * Masters of Advanced Studies in Clinical Research * Ph.D. Program in the Humanities and Social Sciences * Independent Ph.D. programs Opportunities for enrollment in research or degree programs outside of UCSD are also available, and students are encouraged to investigate these, if interested. Sponsors: This program is supported by the University of California at San Diego.

Proper citation: University of California at San Diego, School of Medicine: Graduate Opportunities & Dual Degree Programs (RRID:SCR_001942) Copy   

•   Source: SciCrunch Registry

http://www.alsa.org/

Established in 1985, The ALS Association is the only national non-profit organization fighting Lou Gehrig's Disease on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, The Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure. As the preeminent ALS organization, The Association leads the way in research, care services, public education, and public policy giving help and hope to those facing the disease. The Association's nationwide network of chapters provides comprehensive patient services and support to the ALS community. The mission of The ALS Association is to lead the fight to treat and cure ALS through global research and nationwide advocacy, while also empowering people with Lou Gehrig's Disease and their families to live fuller lives by providing them with compassionate care and support. The ALS Association has committed more than $58 million to find effective treatments and a cure for Lou Gehrig's Disease. Our global research effort has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. Diversity exemplifies The ALS Association's research philosophy. The Association spearheads investigator-initiated projects that originate from the minds of scientists. It also has ALS Association-initiated projects in which research ideas come from a small, blue ribbon committee of scientists who reach out with specific projects for designated scientists in the field. The ALS Association offers multi-year grants to established investigators, as well as one-year starter research awards. The Association is proud to administer The Milton Safenowitz Post-Doctoral Fellowship for ALS Research, which is the only post-doctoral fellowship for ALS research. In addition, The ALS Association's Sheila Essey Award, the premier ALS award, recognizes achievement in research. The ALS Association holds workshops each year that bring together scientists researching ALS and other neurodegenerative diseases to generate new research suggestions and fresh insight. In addition, our TREAT ALS (Transitional Research Advancing Therapy for ALS) initiative combines efficient new drug discovery with priorities set for existing drug candidates to accelerate clinical testing of compounds with promise for the disease. Our Clinical Management Research Program focuses on managing the care of people with ALS in such areas as nutrition, respiration, mobility and psychosocial needs. Since 1998, The Association has funded 21 clinical management research projects representing a total commitment of $750,000. The Association produces a series of manuals and videos as well as a DVD, called Living with ALS, that educate patients about all aspects of the disease.

Proper citation: ALS Association (RRID:SCR_000442) Copy   

•   Source: SciCrunch Registry

http://hospitals.jefferson.edu/diseases-and-conditions/alzheimers-disease/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 6,2023. If you or someone you love has been diagnosed with dementia caused by Alzheimer's disease, you'll be in good hands at Jefferson. Our neurologists and psychiatrists are dedicated to: Compassionate care for individuals with Alzheimer's disease; Supporting families; Advancing care through research into the epidemiology and treatment of neurodegenerative diseases. We interact with patients very early in the disease progression, when impairment is typically mild; deliver state-of-the-art care; provide information; build care-giving skills; and help caregivers connect with community support and plan for the future.

Proper citation: Jefferson Hospital for Neuroscience Alzheimers Disease and Dementia Center (RRID:SCR_000579) Copy   

•   Source: SciCrunch Registry

http://sourceforge.net/projects/variantmaster/

Software program that extracts causative variants in familial and sporadic genetic diseases. The algorithm takes into account predicted variants (SNPs and indels) in affected individuals or tumor samples and utilizes the row (BAM) data to robustly estimate the conditional probability of segregation in a family, as well as the probability of it being de novo or somatic. In familial cases, various modes of inheritance are considered: X-linked, autosomal dominant, and recessive (homozygosity or compound heterozygosity). Moreover, it integrates phenotypes and genotypes, and employs Annovar to produce additional information as allelic frequencies in general population and damaging scores.

Proper citation: VariantMaster (RRID:SCR_000569) Copy   

•   Source: SciCrunch Registry

http://www.genet.sickkids.on.ca/cftr/

Collection of mutations in CFTR gene for international cystic fibrosis genetics research community. Provides up to date information about individual mutations in CFTR gene. All known CFTR mutations and sequence variants have been converted to standard nomenclature recommended by Human Genome Variation Society. On line process for submission of new mutations has been added.While they continue to ensure quality of data, they urge international community to give them feedback and suggestions. Clinical information in this database relates only to details of discovery of specific mutations. As part of 2010 upgrade, CFTR1 joined new project called CFTR2 - Clinical and Functional TRanslation of CFTR. Links to CFTR2 for many mutations in CFTR1 will provide up-to-date summaries of genotype-phenotype information from patient registries around the world.

Proper citation: Cystic Fibrosis Mutation Database (RRID:SCR_000685) Copy   

•   Source: SciCrunch Registry

http://www.ninds.nih.gov/funding/nindsnotes/200707/NIH%20Rapid%20Access%20to%20Interventional%20Development.htm

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 14, 2025.NIH-RAID makes available at no cost to researchers and organizations certain critical resources needed for the development of new therapeutic agents. This program, part of the Translational Research component of Reengineering the Clinical Research Enterprise, uses resources of NCI's Developmental Therapeutics Program and the National Heart Lung and Blood Institutes (NHLBI) Gene Therapy Resource Program. The services provided will depend upon the stage of the project and the strength of the preliminary data. Services available include: production, bulk supply, GMP manufacturing, formulation, development of an assay suitable for pharmacokinetic testing, and animal toxicology. Assistance also will be provided in the regulatory process, through access to independent product development planning expertise. Proposals in support of animal efficacy studies or synthesis and formulation of recombinant proteins or monoclonal antibodies will not be accepted. NIH-RAID is not a grant program. Successful projects will gain access to the governments contract resources, as well as the assistance of the NIH in establishing and implementing a product development plan. Funds to support individual projects will come both from the Roadmap and from individual Institutes, with Institutes assuming the bulk of support in the specific disease areas germane to their mission. This co-sponsorship is critical because of the resource and expertise needs and because NIH-RAID cannot support the full developmental pipeline; an Institute partnership may therefore be important for subsequent translational efforts. To obtain access to NIH-RAID resources, applications must be submitted electronically through Grants.gov using SF424. Applications are initially screened to determine whether the resources requested are appropriate for this program. Then they are reviewed by the NIH Center for Scientific Research. The results of that evaluation along with supplemental information from the lead investigator will guide final Institute and Roadmap resource allocation. The services provided will depend upon the stage of the project and the strength of the preliminary data. When a lead therapeutic agent has been selected and proposed for preclinical development, the following services are available: For small molecules, natural products, peptides, oligonucleotides, and gene vectors: Synthesis, Scale-up production, Development of analytical methods, Development of suitable formulations, Isolation and purification of natural products, Pharmacokinetic/ADME studies including bioanalytical method development, Range-finding initial toxicology, IND-directed toxicology, Manufacture of clinical trial supplies, Product development planning and advice in IND preparation For recombinant proteins and monoclonal antibodies: Pharmacokinetic/ADME studies including bioanalytical method development, Range-finding initial toxicology, IND-directed toxicology, Product development planning and advice in IND preparation When a lead therapeutic agent has not yet been selected and proposed for preclinical development, the following services are available: For small molecules, natural products, peptides, oligonucleotides, and gene vectors: Synthesis, Development of analytical methods, Isolation and purification of natural products, Preliminary Pharmacokinetic/ADME studies, including bioanalytical method development, Preliminary toxicology For recombinant proteins and monoclonal antibodies, Preliminary Pharmacokinetic/ADME studies, including bioanalytical method development, Preliminary toxicology In some cases the NIH-RAID program will support only one or two key steps for preclinical development, while in other cases it may be possible to provide assistance with most of the development tasks needed to file an Investigational New Drug (IND) application to the Food and Drug Administration (FDA). When the NIH-RAID program does not provide all of the remaining services required for IND submission, it is expected that other resources will be in place to complete development steps not supported by NIH-RAID. Funding Resource,.

Proper citation: NIH - Rapid Access to Interventional Development (RRID:SCR_000713) Copy   

•   Source: SciCrunch Registry

http://www.drugabuseresearchtraining.org/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on November 07, 2012. Decemeber 15, 2011 - Thank you for your interest in DrugAbuseResearchTraining.org. The site, courses, and resources are no longer available. Please send an email to inquiry (at) md-inc.com if you would like to be notified if the site or courses become available again. Introduction to Clinical Drug and Substance Abuse Research Methods is an online training program intended to introduce clinicians and substance abuse professionals to basic clinical research methods. The program is divided into four modules. Each module covers an entire topic and includes self-assessment questions, references, and online resources: * The Neurobiology of Drug Addiction * Biostatistics for Drug and Substance Abuse Research * Evaluating Drug and Substance Abuse Programs * Designing and Managing Drug and Substance Abuse Clinical Trials The learning objectives of this program are to help you: * Evaluate the benefits of alternative investigative approaches for answering important questions in drug abuse evaluation and treatment. * Define the proper levels of measurement and appropriate statistical methods for a clinical study. * Address common problems in data collection and analysis. * Anticipate key human subjects and ethical issues that arise in drug abuse studies. * Interpret findings from the drug abuse research literature and prepare a clinical research proposal. * Prepare research findings for internal distribution or publication in the peer reviewed literature. * Recognize drug addiction as a cyclical, chronic disease. * Understand and describe the brain circuits that are affected by addicting drugs, and explain to others the effects of major classes of addicting drugs on brain neurotransmitters. * Utilize new pharmacologic treatments to manage persons with drug addiction. Physicians can earn AMA PRA Category 1 Credit and purchase a high resolution printable electronic CME certificate(view sample); non-physicians can purchase high resolution printable electronic certificate of course participation that references AMA PRA Category 1 credit (view sample). This program does not offer printed certificates.

Proper citation: Online Education for the International Research Community: AboutIntroduction to Clinical Drug and Substance Abuse Research Methods (RRID:SCR_000802) Copy   

•   Source: SciCrunch Registry

http://www2.gsu.edu/~wwwvir/index.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 18,2025. The National B Virus Resource Center is located in the Viral Immunology Center of Georgia State Universitys Department of Biology. Their laboratory is studying viruses that directly affect the central nervous system of infected hosts. Current projects in the laboratory are focused on the molecular biology of human and nonhuman primate alphaherpesviruses and the diseases they cause, immune response characterization, antiviral strategies, including drug discovery and high-throughput drug screening within unique, high containment laboratory suites. They are also actively engaged in the study of unique reoviruses that have the capacity to infect the central nervous systems of non human primates, langur viruses, and a newly isolated mangaby herpesvirus. Alphaherpesviruses target the central nervous system of susceptible hosts, and subsequently establish latent infections generally without severely damaging the host. There may be an initial acute phase when the virus successfully replicates in peripheral tissue of the host. This replication, when it occurs, induces a series of specific immune functions that can serve as markers of infection. We use these markers to design, develop and implement diagnostic assays that will be useful during the management of clinical disease. Each herpesvirus coexists peacefully with the natural host in which it has co-evolved, but when the viruses for any reason find themselves no longer in the natural host, the usual host:parasite relationship may change dramatically. In some closely related hosts the virus can replicate and, in some cases, pathogenesis of the infection is radically more severe than that which occurs in the natural host. For example, this can be seen when New World monkeys are infected with humans herpesviruses, e.g., HSV-1 or HSV-2, or when humans are infected with B virus from a macaque, a member of the Old World monkey family. Their studies focus on the mechanisms by which virus kills the host and how that process can be circumvented with early identification, appropriate antiviral drugs, and in the future, effective vaccines. We continually screen the efficacy of existing as well as novel antiviral agents to inhibit the growth of viruses that can potentially cross into the human population, either through occupational exposure or through more subtle contact. Their laboratory provides a global resource funded by National Institutes of Healths National Center for Research Resources to assist in the identification of zoonotic disease transmissions and develop enhanced strategies to detect virus in macaques. They particularly focus on the transmission of B virus from Asian monkeys to humans who come in contact with them. Members of the genus Macaca include rhesus monkeys, cynomolgus macaques, snow macaques, as well as all other macaques. If the macaque is in the midst of the acute or recurrent infection with B, virus can be transmitted to people who handle these monkeys through cuts, scratches, splashes, bites, or even contaminated equipment or surfaces, i.e., fomites. To counter the effects of this virus, the NIH and Centers for Disease Control and Prevention have instituted a critical set of guidelines for institutions to follow in the event of exposures. Their laboratory provides immediate support to these cases to assist in the rapid diagnosis of B virus infections and to determine the efficacy of selected treatment. Lifetime patient monitoring is provided to identify possible reactivation disease and to better track this unique herpesvirus as it has begun its existence in the human populations. Sponsors: The viral immunology center is funded by National Institutes of Healths National Center for Research Resources.

Proper citation: Viral Immunology Center (RRID:SCR_001089) Copy   

•   Source: SciCrunch Registry

https://medschool.vanderbilt.edu/pharmacology/

At the Department of Pharmacology at Vanderbilt University Medical Center we engage in scientific discovery to elucidate biological mechanisms and develop novel therapeutics. We provide training focused on critical thinking to promote innovation, scholarship and integrity. To this end, we foster creativity, collegiality, and leadership. The Department is one of the most distinguished Pharmacology departments in the country and have placed in the top two NIH ranking positions for sixteen of the last twenty years. Research interests in the Department include five major areas: signal transduction, neuroscience, bioactive lipid metabolism, genetic basis of cardiovascular dysfunction, and drug metabolism. Molecules under investigation include G-protein coupled receptors (rhodopsin, adrenergic, serotonin and receptors), heterotrimeric G-proteins, ion channels, transporters and regulatory proteins such as arrestins, protein kinases and protein phosphatases. A strength in our research and training environment is that Vanderbilt University has a world-acclaimed Division of Clinical Pharmacology, which links the Department of Medicine with the Department of Pharmacology. Faculty members in the Division of Clinical Pharmacology focus on human disease and clinical enigmas as the origin of their questions for research. Basic scientists who pursue their inquiries in this environment are continually informed by their colleagues of the pathophysiological and potential therapeutic relevance that can be achieved by appropriate focus of their efforts. We have created one of the first programs in the country to answer the call from the National Institutes of Health (NIH) for more scientists trained in the area of drug discovery and development. A unique feature of the department is our outstanding Ph.D. training program. Almost 60 scientists in training are addressing important issues in fields such neuroscience, cardiovascular development, receptor signaling, and drug metabolism. Scientists in these areas are linked by a common interest in, and understanding of, the basic principles of drug action and design. This perspective makes our trainees ideally suited for a wide range of careers and our program is committed to developing leaders in academia, industry, and regulatory affairs. Postdoctoral and other positions are available.

Proper citation: Vanderbilt University Medical Center Pharmacology (RRID:SCR_001450) Copy   

•   Source: SciCrunch Registry

http://www.eurorec.org/

An independent not-for-profit organization promoting in Europe the use of high quality Electronic Health Record systems (EHRs). One of its main missions is to support, as the European authorized certification body, EHRs certification development, testing and assessment by defining functional and other criteria. EuroRec is organized as a permanent network of National ProRec centers and provides services to industry (developers and vendors), healthcare providers (buyers), policy makers and patients.

Proper citation: EuroRec (RRID:SCR_004090) Copy   

•   Source: SciCrunch Registry